|Olmesartan||Angiotensin II antagonist|
|Amlodipine||Calcium channel blocker|
Olmesartan/amlodipine, sold under the brand name Azor, among others is a combination medication used to treat high blood pressure. It combines two antihypertensive agents in a film-coated tablet. It contains amlodipine, a calcium channel blocker, and olmesartan medoxomil, an angiotensin-2 receptor antagonist (ARB or A2A). The patent is held by Daiichi Sankyo Pharmaceuticals. Daiichi Sankyo filed a supplemental New Drug Application (sNDA) for Azor with the United States Food and Drug Administration on September 17, 2008. Azor has been studied in clinical trials; one test showed it reduced blood pressure during a 24-hour period and was well tolerated.
Azor is available in different dose preparations: 5 mg/20 mg, 10 mg/20 mg,5 mg/40 mg and 10/40 mg's of amlodipine and olmesartan respectively. One investigation (which included doctors employed by Daiichi Sankyo) concluded that "From a pharmacokinetic perspective, the 2 drugs (amlodipine and olmesartan) are well suited to coadministration in a fixed-dose combination."
- "Daiichi Sankyo, Inc. Files Supplemental New Drug Application for AZOR(R) as Initial..." PR Newswire. Reuters. Sep 17, 2008. Archived from the original on February 1, 2013. Retrieved 2009-10-06.
- Alexander W (June 2009). "American society of hypertension and american urological association". P & T. Pharmacy & Therapeutics. 34 (6): 318–21. PMC 2697919. PMID 19572050.
- "Information about Azor from the manufacturer". Daiichi Sankyo, Inc. 2009-10-06. Archived from the original on 29 September 2009. Retrieved 2009-10-06.
- Rohatagi S, Lee J, Shenouda M, Haworth S, Bathala MS, Allison M, Rubets I, Heyrman R, Noveck R, Salazar DE (November 2008). "Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination". Journal of Clinical Pharmacology. 48 (11): 1309–22. doi:10.1177/0091270008322176. PMID 18974285.
- "Amlodipine mixture with olmesartan". Drug Information Portal. U.S. National Library of Medicine.